Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Daily News

BASIL-3: More Questions Than Answers About Drug-Coated Devices in CLTI

L.A. McKeown

April 24, 2024

News Daily News

DETECT: No Long-term Harm From Paclitaxel Devices in PAD

L.A. McKeown

March 25, 2024

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

L.A. McKeown

October 25, 2023

News Daily News

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

Todd Neale

October 16, 2023

News Conference News

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

L.A. McKeown

November 18, 2022

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

L.A. McKeown

October 12, 2021

News Daily News

German Analysis Supports Long-term Safety of Paclitaxel-Based Therapies

L.A. McKeown

October 09, 2019

News Daily News

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

Caitlin E. Cox

July 11, 2019

News Daily News

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

L.A. McKeown

March 01, 2019

News Daily News

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

L.A. McKeown

February 13, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2018

Shelley Wood

October 02, 2018

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

News Conference News VIVA 2017

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

L.A. McKeown

September 13, 2017

News Conference News ISET 2017

Underappreciated by Clinicians, Critical Limb Ischemia Has Dire Fallout for Patients

Caitlin E. Cox

February 07, 2017

News Daily News

双联抗血小板治疗与高危PAD患者的更佳结果有联系

Leah Lawrence

April 29, 2015

News Daily News

El Tratamiento Antiplaquetario Doble se asoció a Mejores Resultados en Pacientes EAP de Alto Riesgo

Leah Lawrence

April 29, 2015

News Daily News

Dual Antiplatelet Therapy Tied to Better Outcomes in High Risk PAD Patients

Leah Lawrence

April 29, 2015

Advertisement

BASIL-3: More Questions Than Answers About Drug-Coated Devices in CLTI

DETECT: No Long-term Harm From Paclitaxel Devices in PAD

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

German Analysis Supports Long-term Safety of Paclitaxel-Based Therapies

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

TCTMD’s Top 10 Most Popular Stories for September 2018

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

Underappreciated by Clinicians, Critical Limb Ischemia Has Dire Fallout for Patients

双联抗血小板治疗与高危PAD患者的更佳结果有联系

El Tratamiento Antiplaquetario Doble se asoció a Mejores Resultados en Pacientes EAP de Alto Riesgo

Dual Antiplatelet Therapy Tied to Better Outcomes in High Risk PAD Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content